{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T15:23:39Z","timestamp":1767626619627,"version":"build-2065373602"},"reference-count":52,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T00:00:00Z","timestamp":1647388800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Malignant pleural mesothelioma (MPM) is a rare neoplasm whose early diagnosis is challenging and systemic treatments are generally administered as first line in the advanced disease stage. The initial clinical response may represent a useful parameter in terms of identifying patients with a better long-term outcome. In this report, the initial therapeutical response in 46 patients affected with advanced\/unresectable pleural mesothelioma was investigated. The initial therapeutic response was assessed by CT scan and clinical examination after 2\u20133 treatment cycles. Our preliminary evaluation shows that the group of patients treated with regimens including antiangiogenetics and\/or immunotherapy had a significantly better initial response as compared to patients only treated with standard chemotherapy, exhibiting a disease control rate (DCR) of 100% (95% IC, 79.40\u2013100%) and 80.0% (95% IC, 61.40\u201392.30%), respectively. Furthermore, the therapeutic response was correlated with the disease stage, blood leukocytes and neutrophils, high albumin serum levels, and basal body mass index (BMI). Specifically, the patients with disease stage III showed a DCR of 95.7% (95% IC, 78.1\u201399.9%), whereas for disease stage IV the DCR decreased to 66.7% (95% IC, 34.9\u20139.1%). Moreover, a better initial response was observed in patients with a higher BMI, who reached a DCR of 96.10% (95% IC, 80.36\u201399.90%). Furthermore, in order to evaluate in the predictive power of the collected features a multivariate way, we report the preliminary results of a machine learning model for predicting the initial therapeutic response. We trained a state-of-the-art algorithm combined to a sequential forward feature selection procedure. The model reached a median AUC value, accuracy, sensitivity, and specificity of 77.0%, 75%, 74.8%, and 83.3%, respectively. The features with greater informational power were gender, histotype, BMI, smoking habits, packs\/year, and disease stage. Our preliminary data support the possible favorable correlation between innovative treatments and therapeutic response in patients with unresectable\/advanced pleural mesothelioma. The small sample size does not allow concrete conclusions to be drawn; nevertheless, this work is the basis of an ongoing study that will also involve radiomics in a larger dataset.<\/jats:p>","DOI":"10.3390\/jcm11061659","type":"journal-article","created":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T22:09:58Z","timestamp":1647468598000},"page":"1659","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Informative Power Evaluation of Clinical Parameters to Predict Initial Therapeutic Response in Patients with Advanced Pleural Mesothelioma: A Machine Learning Approach"],"prefix":"10.3390","volume":"11","author":[{"given":"Raffaella","family":"Massafra","sequence":"first","affiliation":[{"name":"Struttura Semplice Dipartimentale di Fisica Sanitaria, I.R.C.C.S. Istituto Tumori \u201cGiovanni Paolo II\u201d, Viale Orazio Flacco 65, 70124 Bari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annamaria","family":"Catino","sequence":"additional","affiliation":[{"name":"Struttura Semplice Dipartimentale di Oncologia Medica per la Patologia Toracica, I.R.C.C.S. Istituto Tumori \u201cGiovanni Paolo II\u201d, Viale Orazio Flacco 65, 70124 Bari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pia Maria Soccorsa","family":"Perrotti","sequence":"additional","affiliation":[{"name":"Struttura Semplice Dipartimentale di Radiologia, I.R.C.C.S. Istituto Tumori \u201cGiovanni Paolo II\u201d, Viale Orazio Flacco 65, 70124 Bari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pamela","family":"Pizzutilo","sequence":"additional","affiliation":[{"name":"Struttura Semplice Dipartimentale di Oncologia Medica per la Patologia Toracica, I.R.C.C.S. Istituto Tumori \u201cGiovanni Paolo II\u201d, Viale Orazio Flacco 65, 70124 Bari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2729-9896","authenticated-orcid":false,"given":"Annarita","family":"Fanizzi","sequence":"additional","affiliation":[{"name":"Struttura Semplice Dipartimentale di Fisica Sanitaria, I.R.C.C.S. Istituto Tumori \u201cGiovanni Paolo II\u201d, Viale Orazio Flacco 65, 70124 Bari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Montrone","sequence":"additional","affiliation":[{"name":"Struttura Semplice Dipartimentale di Oncologia Medica per la Patologia Toracica, I.R.C.C.S. Istituto Tumori \u201cGiovanni Paolo II\u201d, Viale Orazio Flacco 65, 70124 Bari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4878-5906","authenticated-orcid":false,"given":"Domenico","family":"Galetta","sequence":"additional","affiliation":[{"name":"Struttura Semplice Dipartimentale di Oncologia Medica per la Patologia Toracica, I.R.C.C.S. Istituto Tumori \u201cGiovanni Paolo II\u201d, Viale Orazio Flacco 65, 70124 Bari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,3,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0140-6736(05)67025-0","article-title":"Malignant mesothelioma","volume":"366","author":"Robinson","year":"2005","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/bjc.2012.245","article-title":"Prognosis and prognostic factors of patients with mesothelioma: A population-based study","volume":"107","author":"Koffijberg","year":"2012","journal-title":"Br. J. Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2782590","DOI":"10.1155\/2017\/2782590","article-title":"Life Expectancy in Pleural and Peritoneal Mesothelioma","volume":"2017","author":"Shavelle","year":"2017","journal-title":"Lung Cancer Int."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Terenziani, R., Zoppi, S., Fumarola, C., Alfieri, R., and Bonelli, M. (2021). Immunotherapeutic Approaches in Malignant Pleural Mesothelioma. Cancers, 13.","DOI":"10.3390\/cancers13112793"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"343","DOI":"10.3389\/fonc.2020.00343","article-title":"Emerging Treatments for Malignant Pleural Mesothelioma: Where Are We Heading?","volume":"10","author":"Cantini","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-018-0191-1","article-title":"Immune checkpoint inhibitors: Recent progress and potential biomarkers","volume":"50","author":"Darvin","year":"2018","journal-title":"Exp. Mol. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e1494111","DOI":"10.1080\/2162402X.2018.1494111","article-title":"Combination immune checkpoint blockade as an effective therapy for mesothelioma","volume":"7","author":"Fear","year":"2018","journal-title":"OncoImmunology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(18)30765-4","article-title":"Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): A multicentre, open-label, randomised, non-comparative, phase 2 trial","volume":"20","author":"Scherpereel","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): A multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S2213-2600(18)30420-X","article-title":"Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): Results of a prospective, single-arm, phase 2 trial","volume":"7","author":"Disselhorst","year":"2019","journal-title":"Lancet Respir. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1016\/j.jtho.2021.01.323","article-title":"PS01.11 Nivolumab Versus Placebo in Relapsed Malignant Mesothelioma: The CONFIRM Phase 3 Trial","volume":"16","author":"Fennell","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1245\/s10434-018-6385-x","article-title":"The C-Reactive Protein\/Albumin Ratio is a Novel Significant Prognostic Factor in Patients with Malignant Pleural Mesothelioma: A Retrospective Multi-Institutional Study","volume":"25","author":"Takamori","year":"2018","journal-title":"Ann. Surg. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jtho.2015.12.108","article-title":"A Novel Clinical Prediction Model for Prognosis in Malignant Pleural Mesothelioma Using Decision Tree Analysis","volume":"11","author":"Brims","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Napoli, F., List\u00ec, A., Zambelli, V., Witel, G., Bironzo, P., Papotti, M., Volante, M., Scagliotti, G., and Righi, L. (2021). Pathological Characterization of Tumor Immune Microenvironment (TIME) in Malignant Pleural Mesothelioma. Cancers, 13.","DOI":"10.3390\/cancers13112564"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s13665-013-0045-1","article-title":"Prognostic factors for malignant pleural mesothelioma","volume":"2","author":"Brims","year":"2013","journal-title":"Curr. Respir. Care Rep."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e565","DOI":"10.1016\/S2589-7500(21)00104-7","article-title":"The use of a next-generation sequencing-derived machine-learning risk-prediction model (OncoCast-MPM) for malignant pleural mesothelioma: A retrospective study","volume":"3","author":"Zauderer","year":"2021","journal-title":"Lancet Digit. Health"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1016\/j.jtho.2021.06.014","article-title":"Mesothelioma Risk Score: A New Prognostic Pretreatment, Clinical-Molecular Algorithm for Malignant Pleural Mesothelioma","volume":"16","author":"Yeap","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.jtho.2017.04.002","article-title":"Epidemiology of Environmental Exposure and Malignant Mesothelioma","volume":"12","author":"Liu","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"15692","DOI":"10.1007\/s11356-018-1618-x","article-title":"Environmental asbestos exposure and mesothelioma cases in Bari, Apulia region, southern Italy: A national interest site for land reclamation","volume":"25","author":"Vimercati","year":"2018","journal-title":"Environ. Sci. Pollut. Res."},{"key":"ref_20","first-page":"1483","article-title":"Diagnosis of mesothelioma with deep learning","volume":"17","author":"Hu","year":"2019","journal-title":"Oncol. Lett."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"102726","DOI":"10.1016\/j.bspc.2021.102726","article-title":"A novel framework for prognostic factors identification of malignant mesothelioma through association rule mining","volume":"68","author":"Alam","year":"2021","journal-title":"Biomed. Signal Process. Control"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Alam, T.M., Shaukat, K., Mahboob, H., Sarwar, M.U., Iqbal, F., Nasir, A., Hameed, I.A., and Luo, S. (2021). A Machine Learning Approach for Identification of Malignant Mesothelioma Etiological Factors in an Imbalanced Dataset. Comput. J.","DOI":"10.1093\/comjnl\/bxab015"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Latif, M.Z., Shaukat, K., Luo, S., Hameed, I.A., Iqbal, F., and Alam, T.M. (2020, January 12\u201313). Risk Factors Identification of Malignant Mesothelioma: A Data Mining Based Approach. Proceedings of the 2020 International Conference on Electrical, Communication, and Computer Engineering (ICECCE), Istanbul, Turkey.","DOI":"10.1109\/ICECCE49384.2020.9179443"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Kidd, A.C., Anderson, O., Cowell, G.W., Weir, A.J., Voisey, J.P., Evison, M., Tsim, S., Goatman, K.A., and Blyth, K.G. (2022). Fully automated volumetric measurement of malignant pleural mesothelioma by deep learning AI: Validation and comparison with modified RECIST response criteria. Thorax.","DOI":"10.1136\/thoraxjnl-2021-217808"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/annonc\/mdh059","article-title":"Modified RECIST criteria for assessment of response in malignant pleural mesothelioma","volume":"15","author":"Byrne","year":"2004","journal-title":"Ann. Oncol."},{"key":"ref_26","unstructured":"Zhang, H. (2004). The Optimality of Naive Bayes, American Association for Artificial Intelligence."},{"key":"ref_27","unstructured":"Breiman, L. (2001). Random Forests Mach Learn, Springer."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"407","DOI":"10.4097\/kjae.2017.70.4.407","article-title":"Statistical data preparation: Management of missing values and outliers","volume":"70","author":"Kwak","year":"2017","journal-title":"Korean J. Anesthesiol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3","article-title":"Index for rating diagnostic tests","volume":"3","author":"Youden","year":"1950","journal-title":"Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e1009285","DOI":"10.1080\/2162402X.2015.1009285","article-title":"The tumoral and stromal immune microenvironment in malignant pleural mesothelioma: A comprehensive analysis reveals prognostic immune markers","volume":"4","author":"Ujiie","year":"2015","journal-title":"OncoImmunology"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1016\/j.jtho.2019.03.029","article-title":"Potential Diagnostic and Prognostic Role of Microenvironment in Malignant Pleural Mesothelioma","volume":"14","author":"Salaroglio","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.3389\/fonc.2019.01519","article-title":"Malignant Pleural Mesothelioma: State-of-the-Art on Current Therapies and Promises for the Future","volume":"9","author":"Nicolini","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"402","DOI":"10.3322\/caac.21572","article-title":"Mesothelioma: Scientific clues for prevention, diagnosis, and therapy","volume":"69","author":"Carbone","year":"2019","journal-title":"CA Cancer J. Clin."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/0169-5002(95)00407-R","article-title":"Serum albumin and other prognostic factors related to response and survival in patients with advanced non-small cell lung cancer","volume":"12","author":"Espinosa","year":"1995","journal-title":"Lung Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1038\/s41591-019-0583-3","article-title":"Deep learning-based classification of mesothelioma improves prediction of patient outcome","volume":"25","author":"Courtiol","year":"2019","journal-title":"Nat. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e000240","DOI":"10.1136\/bmjresp-2017-000240","article-title":"Survival prediction in mesothelioma using a scalable Lasso regression model: Instructions for use and initial performance using clinical predictors","volume":"5","author":"Kidd","year":"2018","journal-title":"BMJ Open Respir. Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1097\/JTO.0000000000000661","article-title":"A new prognostic score supporting treatment allocation for multimodality therapy for malignant pleural mesothelioma: A review of 12 years\u2019 experience","volume":"10","author":"Opitz","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.jtho.2018.04.023","article-title":"New Insights on Diagnostic Reproducibility of Biphasic Mesotheliomas: A Multi-Institutional Evaluation by the International Mesothelioma Panel From the MESOPATH Reference Center","volume":"13","author":"Salle","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.lungcan.2016.06.016","article-title":"Predictive biomarkers of response to PD-1\/PD-L1 immune checkpoint inhibitors in non\u2013small cell lung cancer","volume":"99","author":"Shien","year":"2016","journal-title":"Lung Cancer"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jamaoncol.2019.5241","article-title":"Association Between Body Mass Index and Overall Survival with Immune Checkpoint Inhibitor Therapy for Advanced Non\u2013Small Cell Lung Cancer","volume":"6","author":"Kichenadasse","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/j.jtho.2017.06.011","article-title":"The Obesity Paradox\u2014What Does It Mean for Lung Cancer Surgery?","volume":"12","author":"Stone","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s11912-016-0539-4","article-title":"The Obesity Paradox in Cancer: A Review","volume":"18","author":"Lennon","year":"2016","journal-title":"Curr. Oncol. Rep."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"14123","DOI":"10.1038\/s41598-021-93592-z","article-title":"Early prediction of neoadjuvant chemotherapy response by exploiting a transfer learning approach on breast DCE-MRIs","volume":"11","author":"Comes","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ejmp.2021.04.010","article-title":"Artificial intelligence applications in medical imaging: A review of the medical physics research in Italy","volume":"83","author":"Avanzo","year":"2021","journal-title":"Phys. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"576007","DOI":"10.3389\/fonc.2021.576007","article-title":"A Clinical Decision Support System for Predicting Invasive Breast Cancer Recurrence: Preliminary Results","volume":"11","author":"Massafra","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"La Forgia, D., Fanizzi, A., Campobasso, F., Bellotti, R., Didonna, V., Lorusso, V., Moschetta, M., Massafra, R., Tamborra, P., and Tangaro, S. (2020). Radiomic Analysis in Contrast-Enhanced Spectral Mammography for Predicting Breast Cancer Histological Outcome. Diagnostics, 10.","DOI":"10.3390\/diagnostics10090708"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.1158\/1078-0432.CCR-18-2495","article-title":"Deep Learning Predicts Lung Cancer Treatment Response from Serial Medical Imaging","volume":"25","author":"Xu","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.21037\/tlcr-20-673","article-title":"Immunotherapy in malignant pleural mesothelioma: A review of literature data","volume":"10","author":"Menis","year":"2021","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_49","first-page":"261","article-title":"Double Dipping in Machine Learning: Problems and Solutions","volume":"5","author":"Ball","year":"2020","journal-title":"Biol. Psychiatry Cogn. Neurosci. Neuroimaging"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.ifacol.2015.10.185","article-title":"Machine Learning for Predictive Modelling based on Small Data in Biomedical Engineering","volume":"48","author":"Shaikhina","year":"2015","journal-title":"IFAC-PapersOnLine"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/nn.2303","article-title":"Circular analysis in systems neuroscience: The dangers of double dipping","volume":"12","author":"Kriegeskorte","year":"2009","journal-title":"Nat. Neurosci."},{"key":"ref_52","unstructured":"Fortmann-Roe, S. (2019, September 16). Understanding the Bias-Variance Tradeoff. Available online: http:\/\/scott.fortmann-roe.com\/docs\/BiasVariance.html."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/6\/1659\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:37:36Z","timestamp":1760135856000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/6\/1659"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,16]]},"references-count":52,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,3]]}},"alternative-id":["jcm11061659"],"URL":"https:\/\/doi.org\/10.3390\/jcm11061659","relation":{},"ISSN":["2077-0383"],"issn-type":[{"type":"electronic","value":"2077-0383"}],"subject":[],"published":{"date-parts":[[2022,3,16]]}}}